



Pivoting vs. Shielding Safety Needles

An overview comparing Terumo SurGuard®3, BD Eclipse, Covidien Magellan and BD SafetyGlide*.

We tested two pivoting and two shielding needle designs:



100% of HCPs preferred the pivoting safety designs because they...

- are perceived as more sturdy
- inherently provides audible and tactile feedback after activation
- are designed to easily activate using a hard surface activation (HSA)
- cover the needle after use/activation

SurGuard®3 scored highest among HCPs in terms of **sturdiness** after activation, **ease** of activation and **coverage of needle and cannula** after activation.

SurGuard®3 is engineered for this while other pivoting shield needles are not.

HCPs felt that pivoting designs were more sturdy, providing them with the confidence and security that the device is safe.


Audible feedback gave providers assurance that the safety mechanism was locked over the needle after use.

Shielding devices require additional needle length to allow the shield to rest on the needle prior to activation. Both Magellan **A** and SafetyGlide **B** have this design. Pivoting designs do not require this extra needle length. This “added” needle length does not change the injection length, but increases the overall device size.

Source: Matchstick measurement of 22g x 1.5” commercially available safety needle samples.




Longer, more exposed needles intensify patient and nurse **uncertainty** during injection.



HCPs use hard surface activation half the time (50% of injections in our study), even for products that are not 510(k) cleared for Hard Surface Activation

SurGuard®3



Eclipse and SafetyGlide are not 510(k) cleared for Hard Surface Activation



RX ONLY. The advertisement is directed to physicians only, and not to consumers. Refer to product labels and packaging insert for complete warnings, precautions, potential complications, and instructions for use. Products may not have regulatory approval in all countries. Please contact your local sales representative if you have questions about the availability of products in your area.

*“Simulated use study of four safety needles used to administer LAI medications for schizophrenia” Final study report by Matchstick, 2019.

*The third party trademarks used herein are trademarks of their respective owners.

PM-04307